Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced lupus.

Robert L Rubin1

  • 1Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA. rlrubin@salud.unm.edu

Toxicology
|March 16, 2005
PubMed
Summary
This summary is machine-generated.

Certain medications can trigger drug-induced lupus (DIL) by disrupting T-cell tolerance in the thymus. Recovery occurs after drug discontinuation, suggesting specific mechanisms beyond typical hypersensitivity reactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of circulating and excreted metals and of autoimmunity between two Great Plains Tribal communities.

Journal of autoimmunity·2023
Same author

Urinary Metals Concentrations and Biomarkers of Autoimmunity among Navajo and Nicaraguan Men.

International journal of environmental research and public health·2020
Same author

Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation.

Journal of autoimmunity·2019
Same author

Evolving and expanding scope of lupus-inducing drugs.

Annals of the rheumatic diseases·2019
Same author

Mice Housed at Elevated Vivarium Temperatures Display Enhanced T-cell Response and Survival to <i>Francisella tularensis</i>.

Comparative medicine·2017
Same author

The universe of ANA testing: a case for point-of-care ANA testing.

Auto- immunity highlights·2017
Same journal

Evaluation of 2,2'-Dimorpholinodiethyl Ether (DMDEE) in Pathology, Perinatal, and Genotoxicity Studies.

Toxicology·2026
Same journal

Retraction notice to "Involvement of both intrinsic and extrinsic pathways in hepatoprotection of arjunolic acid against cadmium induced acute damage in vitro" [Toxicology 283 (2011) 129-139].

Toxicology·2026
Same journal

Crystalline silica particles exposure modulated miRNA expression profiles in human macrophage-like THP-1 cells.

Toxicology·2026
Same journal

Sex-specific cellular and molecular mechanisms of PFAS-induced reproductive toxicity.

Toxicology·2026
Same journal

Neurotoxicity and mechanisms of deltamethrin and its metabolite 3-PBA in HT22 cells.

Toxicology·2026
Same journal

Polystyrene nanoplastics impair epithelial barrier establishment and modulate extracellular vesicle release in human bronchial cells cultured at the air-liquid interface.

Toxicology·2026
See all related articles

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Medications can induce autoantibodies and rheumatic symptoms, leading to distinct syndromes like drug-induced lupus (DIL).
  • DIL shares features with systemic lupus erythematosus but resolves upon withdrawal of the causative agent.
  • Unlike typical drug hypersensitivity, DIL involves prolonged drug exposure, dose-dependency, and lacks drug-specific immune sensitization.

Purpose of the Study:

  • To explore the mechanisms underlying drug-induced autoimmunity.
  • To investigate the role of T-cell tolerance disruption in the thymus in DIL pathogenesis.
  • To differentiate DIL from other drug-related immune reactions.

Main Methods:

  • Review of clinical and laboratory features of DIL.

Related Experiment Videos

  • Analysis of exposure history in relation to DIL development.
  • Utilizing a mouse model to study the effects of drug metabolites on thymic function and autoimmunity induction.

    • Main Results:

    • Circumstantial evidence suggests oxidative drug metabolites trigger autoimmunity.
    • Potential mechanisms include bystander activation, direct cytotoxicity, and disruption of central T-cell tolerance.
    • A mouse model demonstrated that a procainamide metabolite in the thymus induces lupus-like autoantibodies.

    Conclusions:

    • Abnormalities in thymic T-cell selection are implicated in initiating autoimmunity in DIL.
    • Drug-induced lupus pathogenesis involves complex immune dysregulation potentially originating in the thymus.
    • Findings support a distinct mechanism for DIL compared to drug hypersensitivity.